Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer-Reference-Cited by-同舟云学术

Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer

Published:2011-12-29 Issue:1 Volume:55 Page:169-196
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

William Anthony D.¹,Lee Angeline C.-H.¹,Goh Kee Chuan¹,Blanchard Stéphanie¹,Poulsen Anders¹,Teo Ee Ling¹,Nagaraj Harish¹,Lee Chai Ping¹,Wang Haishan¹,Williams Meredith¹,Sun Eric T.¹,Hu Changyong¹,Jayaraman Ramesh¹,Pasha Mohammed Khalid¹,Ethirajulu Kantharaj¹,Wood Jeanette M.¹,Dymock Brian W.¹

Affiliation:

1. S*BIO Pte. Ltd., 1 Science Park Road, No. 05-09, The Capricorn, Singapore Science Park II, 117528, Singapore

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm201112g

Reference41 articles.

1. The Era of Cancer Discovery

2. Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling

3. Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers: Fig. 1.

4. Sorafenib: delivering a targeted drug to the right targets

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Development of CDK2 Inhibitors as Anticancer Drugs: An Update (2015–2023);Pharmaceutical Fronts;2024-09-03

2. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

3. Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy;Molecules;2024-06-26

4. Rational Molecular Editing: A New Paradigm in Drug Discovery;Journal of Medicinal Chemistry;2024-06-21

5. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications;Journal of Medicinal Chemistry;2024-04-02